Treatment for Hepatopulmonary Syndrome
Liver transplantation is the only definitive and curative treatment for hepatopulmonary syndrome, with complete resolution occurring in over 90% of patients within 6-12 months post-transplant. 1, 2
Immediate Management: Supportive Care
While awaiting transplantation, the primary intervention is long-term supplemental oxygen therapy, particularly during physical activity and in patients with severe hypoxemia (PaO2 <60 mmHg) 1, 2. However, it's important to note that no data exists regarding the effectiveness, tolerance, or impact on survival of oxygen therapy—it remains the only available supportive measure.
Medical Therapies: Uniformly Ineffective
No pharmacological treatment has proven effective for HPS 2. The following have been tested and failed:
- Beta-blockers
- Cyclooxygenase inhibitors
- Systemic glucocorticoids and cyclophosphamide
- Almitrine bismesylate
- Inhaled nitric oxide and nitric oxide inhibitors
- Antimicrobial agents
- Pentoxifylline (contradictory results with frequent GI side effects)
TIPS is not recommended for HPS treatment, as data is insufficient and there is concern it may worsen pulmonary vasodilation by exacerbating hyperkinetic circulation 2.
Definitive Treatment Algorithm
For Cirrhotic Liver Disease with HPS:
Proceed directly to liver transplant evaluation 1. This is appropriate for all patients with cirrhotic liver disease and HPS, regardless of severity.
For Non-Cirrhotic Portal Hypertension with HPS:
First assess for congenital/acquired portosystemic shunts 1:
If identifiable shunt present: Consider shunt closure as alternative to transplant
- Surgical ligation of the shunt
- Endovascular occlusion device placement by interventional radiology
- Examples: Abernethy syndrome, congenital portosystemic communications
If no correctable shunt or closure not feasible: Proceed to liver transplantation 1
Transplant Prioritization Based on Severity:
Severe HPS (PaO2 <60 mmHg) receives MELD exception points (initial score of 22, with increases every 3 months) to ensure transplantation within a reasonable timeframe 2. This policy has improved 5-year survival from 67% in the pre-MELD era to 88% in the MELD era 2.
Critical threshold: Median survival without transplant in severe HPS (PaO2 <50 mmHg) is less than 12 months 1, 3. Pre-transplant PaO2 ≤44 mmHg is associated with increased post-transplant mortality 2.
Post-Transplant Outcomes
- HPS resolution: 90.1% at 6 months, with complete resolution within 1 year in all assessed patients 4
- Post-transplant survival: 1-year survival of 85.5-93.9% and 5-year survival of 76-92.9%, comparable to patients without HPS 4
- Important caveat: Respiratory function typically worsens in the first days post-transplant due to the surgical procedure itself, with improvement taking months 5
Screening Protocol
All patients with portosystemic shunting (cirrhotic or non-cirrhotic) should undergo regular screening with room air pulse oximetry in an upright position 1. Arterial blood gas analysis should be performed every 6 months in patients with confirmed HPS to monitor for progression 2.
Key Clinical Pitfalls
- Do not delay transplant evaluation: HPS worsens over time with a median decrease in PaO2 of 5.2 mmHg per year 2
- Very severe hypoxemia (PaO2 <50 mmHg) with no reversibility to 100% oxygen carries risk of irreversible respiratory failure post-transplant and high perioperative mortality 5
- HPS can occur without liver dysfunction (e.g., congenital hepatic fibrosis, portal vein thrombosis)—portal hypertension alone is sufficient 1
- Coil embolization may temporarily improve oxygenation in angiographic arteriovenous communications but is not a definitive treatment 2